Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jul 12;18(7):e0288260. doi: 10.1371/journal.pone.0288260

In vitro and in silico studies for the identification of anti-cancer and antibacterial peptides from camel milk protein hydrolysates

Mohammad Javad Taghipour 1, Hamid Ezzatpanah 1,*, Mohammad Ghahderijani 2
Editor: Ghulam Mustafa3
PMCID: PMC10337890  PMID: 37437001

Abstract

Today, breast cancer and infectious diseases are very worrying that led to a widespread effort by researchers to discover natural remedies with no side effects to fight them. In the present study, we isolated camel milk protein fractions, casein and whey proteins, and hydrolyzed them using pepsin, trypsin, and both enzymes. Screening of peptides with anti-breast cancer and antibacterial activity against pathogens was performed. Peptides derived from whey protein fraction with the use of both enzymes showed very good activity against MCF-7 breast cancer with cell viability of 7.13%. The separate use of trypsin and pepsin to digest whey protein fraction yielded peptides with high antibacterial activity against S. aureus (inhibition zone of 4.17 ± 0.30 and 4.23 ± 0.32 cm, respectively) and E. coli (inhibition zone of 4.03 ± 0.15 and 4.03 ± 0.05 cm, respectively). Notably, in order to identify the effective peptides in camel milk, its protein sequences were retrieved and enzymatically digested in silico. Peptides that showed both anticancer and antibacterial properties and the highest stability in intestinal conditions were selected for the next step. Molecular interaction analysis was performed on specific receptors associated with breast cancer and/or antibacterial activity using molecular docking. The results showed that P3 (WNHIKRYF) and P5 (WSVGH) peptides had low binding energy and inhibition constant so that they specifically occupied active sites of protein targets. Our results introduced two peptide-drug candidates and new natural food additive that can be delivered to further animal and clinical trials.

Introduction

Research has shown that breast cancer is associated with infectious diseases [1]. According to the WHO reports [2], breast cancer is the most prevalent cancer in the world with about 7.8 million women diagnosed by the end of 2020. This organization has also informed that 55% of global deaths have occurred by infectious diseases in 2019. These alarming statistics have prompted researchers around the world to look for a way to control them. On condition that the breast cancer is identified in the early stages, the treatment can achieve a survival possibility of 90% or higher. For this, the use of anticancer drugs including chemotherapy, endocrine therapy, and targeted biologic therapy such as peptides, antibodies, and secondary metabolites are very common.

The worldwide sales of peptide drugs were reached to US$ 70 billion in 2019 [3], which reveals a lot of attention has been paid to peptide-based drugs. Milk is a source of bioactive peptides which are inactively located within the parent protein sequences [4, 5]. These peptides are released from parental protein sequences using hydrolysis and cause a variety of biological activities, including antiviral [6], opioid [7], antithrombotic [8], antihypertensive [9], and antioxidant [10, 11]. They provide other benefits in comparison with proteins, including being small in size and more easily passing through the digestive tract, low osmotic pressure, low antigenicity, good taste, easy synthesis, and easily recombinant production [12].

Previous researches reported antibacterial and anticancer peptides from mammalian milk proteins by hydrolysis using various enzymes, including pepsin, trypsin, chymosin, chymotrypsin [13, 14]. The hydrolysates of camel milk proteins have exhibited some other biological activities, including antioxidant, antihypertensive, antidiabetic, anti-inflammatory, and anticholesterolemic [1518]. It seems that, camel milk is an excellent and interesting food source can provide therapeutic peptides which will contribute to both nutrition and human health through use as natural ingredients in food or drugs [16, 19]. Consumption of camel milk is common among peoples because of its similarity to human milk [20]. Camel milk is consisted two main protein fractions including casein; αS1-, αS2-, β-, and κ-casein, and whey proteins; α-lactalbumin, serum albumin, lactoferrin, lactophorin, immunoglobulins, some peptides and lacks of β-lactoglobulin [20].

Peptide screening and computational biology will support the discovery of drugs. However, new methods must be complemented by laboratory studies in order to provide results that are more accurate. It would be very promising to find anticancer drugs that cannot only control the progression of cancer but also subsequent infectious diseases. The aim of this study was to investigate and identify various anti-breast cancer and antibacterial peptides from different camel milk protein fractions. Firstly, we studied their biological properties in vitro and then identified effective peptides using bioinformatics tools, followed by analyzing physicochemical properties and their binding to specific receptors using molecular docking.

Materials and methods

In vitro protein preparation

Camel milk (Camelus dromedarius) was purchased from the local market in Shiraz, Iran, followed by stored at -20 °C. The casein and serum proteins were fractioned according to the previously described method [21] with some modifications. Briefly, camel milk was defatted using a centrifuge at 4255 ×g at 4 °C for 15 min. Afterward, the pH of defatted milk was adjusted to 4.6 (isoelectric pH of casein) using 1N HCl and then allowed to settle at 4 °C for 30 min followed by centrifugation at 10000 ×g at 4 °C for 15 min. The precipitated casein fraction was collected and washed twice with ddH2O. The supernatant was again centrifuged at the above condition for 60 min and supernatant, as whey protein fraction, was collected. The pH of casein and whey protein fractions was adjusted to 7.0 and afterward lyophilized and stored at -20 °C for the next analysis.

In vitro enzymatic digestion

Lyophilized proteins were dissolved in double distilled water and enzymatic digestion was performed using pepsin, trypsin, and both in the optimum conditions. These enzymes were selected based on gastrointestinal simulated condition. Briefly, hydrolysis was conducted in the ratio of 1:25 enzyme to protein at 37 °C and pH of 2.5 for 12 h using pepsin, whereas it was in the same conditions with a pH of 7.5 using trypsin. In the combination of both enzymes, the first hydrolysis was conducted using pepsin. After the inactivation of pepsin, the second hydrolysis was conducted using trypsin. Finally, each reaction was heated at 95 °C for 20 min to inactivate enzyme and the samples were centrifuged at 12000 ×g for 30 min followed by collecting the supernatant. Hydrolysates were lyophilized and stored at -20 °C for further analysis.

Determining the hydrolysis degree

Hydrolysis degree of hydrolysates over time was determined according to the previously described method [22]. Briefly, sampling was conducted at 0, 1, 2, 4, 6, and 12 h after hydrolysis and the content of α-amino nitrogen was determined using the OPA method. The degree of hydrolysis was calculated using the following equations:

Serine-NH2=ODsampleODblank/ODstandardODblank×0.9516×0.1×100/X×P
h=serine-NH2β/αmeqv/gprotein
DH%=h/htot×100

Whereas X and P are gram of sample and the percentage of protein in sample, respectively. In addition, α, β, and htot are equal to 1.039, 0.383, and 8.2 for casein and 1.00, 0.40, and 8.8 for whey proteins.

Antibacterial activity

The antibacterial activity of hydrolysates was evaluated using the agar well diffusion method according to the described method elsewhere [23] with minor alterations. Briefly, four bacterial strains of Klebsiella pneumoniae (PTCC 1053), Pseudomonas aeruginosa (PTCC 1074), Staphylococcus aureus (PTCC 1112), and Escherichia coli (PTCC 1330) were cultured in the liquid LB medium overnight at 37 °C. Afterward, each strain was prepared at 0.5 McFarland standard. For antibacterial screening, 1 mL of bacteria inoculum was mixed with solid LB medium and poured into the petri dish. After solidification, the wells were created and 150 μL of each hydrolysate at 400 μg/mL was pipetted into each well. The plates were incubated at 4 °C for diffusing followed by at 37 °C for 18 h. The inhibition potency of each hydrolysate was measured using the diameter of appeared halo.

Anticancer activity

The anticancer activity of hydrolysates was evaluated using the MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)) assay according to the previously reported methods [24, 25]. For this purpose, the MCF-7 breast cancer cell line was maintained in RPMI-1640 medium at 37 °C and 5% CO2 in a humid atmosphere. Thereafter, 1 × 104 cells were seeded into each well of the 96-well plate and incubated at 37 °C and 5% CO2 for 24 h. Afterward the medium was removed and hydrolysates diluted in the medium at 400 μg/mL followed by add on plate being incubated under the above conditions for 24 h. The treatments were removed and MTT dye prepared in medium (0.5 mg/mL/well) was added. The plate was again incubated under the above conditions for 4 h and then MTT dye was removed. The cells were treated with DMSO (dimethyl sulfoxide) and incubated under the above conditions for 15 min. Finally, the absorbance was measured at 570 nm using a microplate reader. The cell viability percentage was calculated by the described equation elsewhere [26] and IC50 value was calculated.

Statistical analysis

All experiments were done in triplicates and results were expressed as mean ± SD. Statistical analysis and mean comparison were performed in the form of a completely random design using SAS 9.4 (Institute Inc., Cary, NC, USA) and the Tukey test, respectively. Drawing graphs and calculating the IC50 value were done using GraphPad Prism software.

Protein sequences

The protein sequences of the milk of camel (Camelus dromedarius), including alpha-S1-casein (accession number: O97943), alpha-S2-casein (O97944), beta-casein (Q9TVD0), kappa-casein (L0P3Z7), albumin (A0A5N4EFP0), and alpha-lactalbumin (A0A5N4DFK4), were retrieved from the UniProt database (https://www.uniprot.org/).

In silico enzymatic digestion and screening

The milk protein sequences were applied to digest using the Peptide Cutter Server (http://www.expasy.ch/tools/peptidecutter/) with pepsin and trypsin enzymes individually (S1 Table in S1 File). Derived peptides were screened for anticancer and antimicrobial activities using the AntiCP 2.0 server (https://webs.iiitd.edu.in/raghava/anticp2) with SVM threshold of 0.6 and both methods of Model 1 and 2, and the Antimicrobial Peptide Scanner vr.2 (https://www.dveltri.com/ascan/v2/ascan.html) server with probabilities of 0.6, respectively. Afterward, the half-life of peptides that showed both anticancer and antimicrobial activity was evaluated in intestinal conditions using the HLP server (http://crdd.osdd.net/raghava/hlp/pep_both.htm) with SVM based model, followed by peptides with high half-life and high stability selected for further analysis (Table 1).

Table 1. The main peptides used for further analysis in this study.

Number Source Peptide sequence AntiCP score AntiMP score Half-life (sec.) Stability
Model 1 Model 2
P1 alpha-S1-casein ARPKY < 0.60 0.61 0.63 1.36 High
P2 alpha-S1-casein LIPRVKL 0.64 0.66 0.75 1.87 High
P3 alpha-S2-casein WNHIKRYF 0.72 < 0.60 0.87 1.43 High
P4 alpha-S2-casein FFIFTCLLAVVLAK 0.62 0.69 0.99 1.10 High
P5 albumin WSVGH 0.77 < 0.60 0.66 1.27 High
P6 albumin LGRVGTKCCTL < 0.60 0.68 0.88 1.32 High
P7 albumin AACLLPK 0.81 0.66 0.82 2.68 High
P8 alpha-lactalbumin FTKCKL < 0.60 0.73 0.88 2.50 High

Note: AntiCP and AntiMP scores indicated the scores retrieved from the AntiCP and Antimicrobial Peptide Scanner servers, respectively. Half-life indicates the half-life of peptides in the intestinal conditions.

Analysis of physicochemical properties

To raise our knowledge of a better understanding of the derived peptides (Table 1), their physicochemical properties, including the molecular weight, theoretical pI, amino acid composition, the number of negatively charged residues (Asp + Glu), the number of positively charged residues (Arg + Lys), atomic composition, total number of atoms, aliphatic index, and grand average of hydropathicity (GRAVY), were analyzed using the ProtParam tool (https://web.expasy.org/protparam/).

Receptor and ligand preparation

Three-dimensional structure model of peptides presented in Table 1 was predicted using the PEP-FOLD 3.5 server (https://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py#forms::PEP-FOLD3). According to the mode of action of antimicrobial agents in the inactivation of bacteria, we selected four receptors including penicillin-binding protein 1a (PBP1a: as inhibitors of cell wall synthesis), isoleucyl-tRNA synthetase (IARS: as inhibitors of protein synthesis), DNA gyrase (as inhibitors of nucleic acid synthesis), dihydrofolate reductase (DHFR: as antimetabolites) and their crystal structure obtained from the Protein Data Bank (https://www.rcsb.org/) with PDB entry of 3UDI, 1JZQ, 3TTZ, and 3SRW, respectively. In addition, the crystal structure of two receptors, which overexpress in breast cancer including Myeloid Cell Leukemia 1 (MCL-1) and estrogen alpha (ERα), were obtained from the Protein Data Bank with PDB entry of 5FDO and 1G50, respectively. All receptors were introduced into the AutoDock Tools (the Scripps Research Institute, La Jolla, CA, USA) software and prepared for docking by adding AD4 type atoms, removing all water molecules except A-2 from 3TTZ and 128 from 3SRW, which are essential for correct docking pose, and adding Kollman charge and polar hydrogens. Afterward, they were used for molecular docking.

Molecular docking and visualization

Molecular docking was performed using the AutoDock Vina 1.1.2 software (the Scripps Research Institute, La Jolla, CA, USA). The active site residues of each receptor were identified from previously reported literature [2733] and the grid box was set on these residues followed by each analysis was independently run three times. The results were presented as the binding energy (Kcal/mol) and the inhibition constant (Ki) [33]. The inhibition constant was calculated from the binding energy according to the following equation: ΔG = RTlnKi, whereas ΔG, R, and T are binding energy (cal/mol), gas constant (1.987 cal/K mol), and temperature (310.15 K), respectively. After docking analysis, the receptor-ligand complexes were visualized using the PyMol software to illustrate interactions.

Results and discussion

Hydrolysis degree

The measurement of hydrolysis degree in proteolytic reactions is one of the important methods to assess the correctness of the reaction. Hence, we determined this factor over time using a method described in the material and method section [22]. The results showed that the hydrolysis degree increased by increasing the time (Fig 1). At time 0, no hydrolysis has taken place, so that the degree of hydrolysis of the parent proteins varied from 1.9 to 2.8% and increased over time with the addition of enzymes (Fig 1). It indicates that enzymatic digestion was done and derived peptides were evaluated for their probable antibacterial and anticancer activities. By the way, it should be noted that the hydrolysis degree of casein and whey proteins fractions was more than others when both enzymes were used (Fig 1).

Fig 1. Determining the hydrolysis degree of hydrolysates over time.

Fig 1

Data are expressed as the mean of a triplicate experiment.

Antibacterial activity

Bioactive peptides are used as alternative drugs or food preservative due to their important role in innate immunity and antimicrobial activity. Today, they are utilized as significant ingredients in functional foods, pharmaceuticals, and nutraceuticals. We evaluated the antibacterial activity of camel milk protein-derived peptides to introduce potential source of food additive or drug candidates. Regarding casein hydrolysis, the highest antibacterial activity was observed in casein-derived peptides by trypsin, showed the highest antibacterial activity against K. pneumoniae and S. aureus (Table 2). By the way, the hydrolysis of casein by both enzymes was reduced the antibacterial potency of hydrolysates in comparison with casein hydrolysis by trypsin, which could be due to more digestion of actual antibacterial peptides. On the other hand, casein hydrolysis by pepsin was produced the best antibacterial peptides against E. coli, whereas casein hydrolysis by both enzymes revealed a good antibacterial effect against P. aeruginosa in comparison with separately used enzymes. Intact casein fraction showed no antibacterial activity.

Table 2. Evaluation of antibacterial activity of protein hydrolysates (400 μg/ml) derived by various enzymes.

Protein Enzyme K. pneumoniae P. aeruginosa S. aureus E. coli
Casein None 0.0c 0.0b 0.0d 0.0c
Trypsin 2.77 ± 0.25a 1.32 ± 0.63ab 3.10 ± 0.10a 1.07 ± 0.30b
Pepsin 0.77 ± 0.25b 1.4 ± 0.53ab 2.30 ± 0.30b 2.37 ± 0.32a
Pepsin + Trypsin 2.13 ± 0.15a 2.03 ± 0.15a 1.03 ± 0.15c 0.73 ± 0.25bc
Whey None 0.0b 0.0b 0.0c 0.0c
Trypsin 0.93 ± 0.30a 1.0 ± 0.10a 4.17 ± 0.30a 4.03 ± 0.15a
Pepsin 0.90 ± 0.26a 1.03 ± 0.25a 4.23 ± 0.32a 4.03 ± 0.05a
Pepsin + Trypsin 0.87 ± 0.15a 0.90 ± 0.26a 2.03 ± 0.25b 1.93 ± 0.20b

Note: The numbers are the size of inhibition zone (cm). Letters separately indicates a significant level at P-value ≤ 0.01 in each group. Data are expressed as mean ± SD from two independent triplicate experiments.

Non-hydrolyzed whey protein fraction showed no antibacterial activity, but hydrolysis by trypsin or pepsin revealed antibacterial activity against the S. aureus and E. coli better than casein-derived peptides (Table 2). Although these peptides showed antibacterial activity against K. pneumoniae and P. aeruginosa, no significant difference was observed between trypsin, pepsin, and both enzymes hydrolysis. A previous study has showed that hydrolysis of casein and whey proteins from Etawa goat milk by bromelain enzyme is able to inhibit the growth of S. aureus and E. coli with a maximum inhibition zone of 2.68 and 3.05 mm, respectively [34]. Furthermore, Jrad et al. [35] showed that hydrolysis of dromedary lactoferrin using pepsin led to an increase in the growth inhibition of Listeria innocua by 28.4% at 0.5 mg/mL compared to unhydrolyzed lactoferrin (inhibition percentage of < 10% at 1 mg/mL). Apart from the direct use of proteases, microbial fermentation of camel milk proteins leads to the production of antibacterial peptides. Hence, Muhialdin and Algboory [36] identified 23 peptides from the hydrolysates of different camel milk proteins fermented by Lactobacillus plantarum, which were able to exhibit antibacterial activity against S. faecalis, Shigella dysenteriae, S. aureus, and E. coli. Another study has indicated that camel whey proteins hydrolysis by trypsin at 40 °C for 4 h has ability to killing S. aureus, E. coli, Salmonella typhimurium, and Streptococcus mutans with an inhibition zone of 11.90, 14.53, 8.36, and 5.60 mm, respectively [37]. Recent study revealed that the temperature and time used to hydrolysis can affect the generation of antibacterial peptides in comparison with our work at 37 °C for 12 h. Therefore, optimization of hydrolysis conditions by each enzyme is essential to achieve the maximum effect. We, in turn, can say that hydrolysis of camel milk proteins, depending on the type of target bacterium; can be good candidates for developing new peptide-based drugs or natural food preservative.

Anticancer activity

For the time being, finding the emerging solutions for tackling breast cancer and consequential infectious diseases is very important. Therefore, the use of hydrolysates of food proteins as anticancer agents is a good option for the development of peptide-based drugs due to their lack of side effects since several anticancer peptide-based drugs have been approved [38]. Accordingly, we evaluated the anticancer activity of camel milk protein hydrolysates against the MCF-7 cell line. The results showed that hydrolysis of whey proteins reveals an anticancer activity better than casein counterparts (Fig 2). When whey protein hydrolysates derived from both enzymes were tested at 400 μg/mL, the cell viability percentage was decreased to 7.13% in comparison with intact whey proteins (74.23%). It was assumed that the isolation of effective peptides has the potential to become a potent peptide-based drug. Otherwise, the casein protein hydrolysates showed anticancer activity, i.e., a cell viability percentage of 57.46%, 63.11%, and 72.42% for trypsin-, pepsin-, and both enzymes (pepsin and trypsin)-derived hydrolysates, respectively, where their inhibition potency was not comparable with whey proteins hydrolysates. On the other hand, whey and casein proteins (parent proteins that used as control) respectively killed approximately 30% and 10% of total cancerous cells, which is lower than anticancer activity of hydrolysates (Fig 2). Although, Homayouni-Tabrizi and co-workers showed that the isolated peptides from hydrolysates derived from camel whey proteins by pepsin and pancreatin revealed no significant anticancer activity against the HepG2 cell line [39]. Previous studies have shown that camel whey protein hydrolysates by pepsin (P-5.2) reveal a good anticancer activity against the HCT116 cell line with an IC50 of 221 μg/mL [40]. Also, it is reported that the isolated peptides from Buffalo whey proteins are able to inhibit the growth of the Caco-2 cell line at 800 μg/mL for 24 h [41]. Therefore, our results in combination with previous studies have provided a good foundation for further study into camel milk protein hydrolysates and their ability to become a potential peptide-based therapeutic agent for cancer.

Fig 2. Anticancer activity of hydrolysates against MCF-7 breast cancer cell line using the MTT assay method.

Fig 2

Data are expressed as mean ± SD from two independent triplicate experiments. Letters indicate a significant level at P-value ≤ 0.01 for comparing each hydrolysate with its control.

In silico screening

The screening of bioactive compounds using computer is a powerful, cost-effective, and short time method. Consequently, we retrieved the protein sequences in camel’s milk from the UniProt database and then digested them in silico using the pepsin and trypsin enzymes individually. After digestion, about 374 peptides were derived and used for screening based on the potency of their antimicrobial and anticancer activities (S1 Table in S1 File). Among them, nine peptides showed both anticancer and antimicrobial activity with a probability more than 0.6. These peptides evaluated based on their stability in intestinal condition and eight of them showed high stability (Table 1). Afterward in order to better understand the properties affecting the potency of peptides, their physicochemical properties were investigated.

Physicochemical properties

Physicochemical properties of peptides can reveal the potential of their bioactivity. Hence, evaluating these features is a shortcut to the final aims. The linear antimicrobial peptides, including anticancer peptides, are positively charged and abundant in histidine and hydrophobic amino acids, including phenylalanine, isoleucine, leucine, and tryptophan, which is an inherent feature of them for facilitating α-helix formation in the membrane [42, 43]. Thus, P3 and P4 were rich in these residues. Furthermore, P5 was rich in histidine and tryptophan residues. This indicates that these peptides are more effective against bacteria or cancer in comparison with other peptides, including P1, P2, P6, P7, and P8 (Table 3).

Table 3. The physicochemical properties of desired peptides using the ProtParam tool.

Physicochemical properties P1 P2 P3 P4 P5 P6 P7 P8
Amino acid composition (% w/w)
Ala (A) 20.0 00.0 00.0 14.3 00.0 00.0 28.6 00.0
Arg (R) 20.0 14.3 12.5 00.0 00.0 09.1 00.0 00.0
Asn (N) 00.0 00.0 12.5 00.0 00.0 00.0 00.0 00.0
Asp (D) 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0
Cys (C) 00.0 00.0 00.0 07.1 00.0 18.2 14.3 16.7
Gln (Q) 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0
Glu (E) 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0
Gly (G) 00.0 00.0 00.0 00.0 20.0 18.2 00.0 00.0
His (H) 00.0 00.0 12.5 00.0 20.0 00.0 00.0 00.0
Ile (I) 00.0 14.3 12.5 07.1 00.0 00.0 00.0 00.0
Leu (L) 00.0 28.6 00.0 21.4 00.0 18.2 28.6 16.7
Lys (K) 20.0 14.3 12.5 07.1 00.0 09.1 14.3 33.3
Met (M) 00.0 00.0 00.0 00.0 00.0 00.0 00.0 00.0
Phe (F) 00.0 00.0 12.5 21.4 00.0 00.0 00.0 16.7
Pro (P) 20.0 14.3 00.0 00.0 00.0 00.0 14.3 00.0
Ser (S) 00.0 00.0 00.0 00.0 20.0 00.0 00.0 00.0
Thr (T) 00.0 00.0 00.0 07.1 00.0 18.2 00.0 16.7
Trp (W) 00.0 00.0 12.5 00.0 20.0 00.0 00.0 00.0
Tyr (Y) 20.0 00.0 12.5 00.0 00.0 00.0 00.0 00.0
Val (V) 00.0 14.3 00.0 14.3 20.0 09.1 00.0 00.0
Molecular weight (Da) 633.75 838.1 1163.35 1585.02 584.63 1150.42 714.92 738.94
Theoretical pI 9.99 11 9.99 8.22 6.74 8.96 8.27 9.31
Number of negatively charge residues 0 0 0 0 0 0 0 0
Number of positively charge residues 2 2 2 1 0 2 1 2
Atomic composition
C 29 40 57 80 27 47 32 34
H 47 75 78 125 36 87 58 58
N 9 11 16 15 8 15 8 8
O 7 8 11 16 7 14 8 8
S 0 0 0 1 0 2 1 1
Total number of atoms 92 134 162 237 78 165 107 109
Aliphatic index 20 208.57 48.75 167.14 58 97.27 140 65
GRAVY - 1.9 0.9 - 1.25 2.44 - 0.22 0.56 1.17 0.1

Note: The negatively and positively charge residues are included Asp + Glu and Arg + Lys, respectively.

GRAVY: Grand average of hydropathicity.

On the other hand, earlier literature has indicated that the pore formation by peptides happens in hydrophobicity thresholds ranging from—0.3 to 0 kcal/mol, and a net charge threshold of 2 [44]. According to this, P5 with a GRAVY score of—0.22 may reveal a bactericidal effect by using pore formation or a mode of action related to membrane disorders. Among all, P1 and P3 had a net charge of + 2 and were the most hydrophobic (Table 3). Also, it is indicated that all peptides rich in particular amino acids, such as arginine, tryptophan, proline, glycine, cysteine, and histidine reveal antimicrobial activity, as seen in this study (Table 3) [42].

In the case of peptides that contain histidine, such as P3 and P5, histidine is an opportune residue to control pH and cationic ion sensing for facilitating cell penetration, so that its targets also may be intracellular. In addition, the presence of histidine causes the formation of stable non-covalent complexes with acidic residues such as phosphate groups [42]. Generally, the modes of action and potency of antimicrobial peptides determine by some of these physicochemical properties, which is highlighted in each peptide.

Molecular docking analysis

Molecular docking, one of the most fundamental and noteworthy strategies in drug discovery, studies the binding mode of a ligand in the active site of proteins [45]. To evaluate the mode of action of desired peptides, we performed molecular docking analysis using AutoDock Vina and showed the bound state, binding energy, and inhibition constant of them against various proteins involved in growth and development of bacteria or breast cancer. Accordingly, all peptides showed a good binding mode to protein targets (S1-S6 Figs in S1 File), so that some of them made a more specific interaction. For instance, P4 just made an interaction with DNA gyrase protein with a binding energy less than others did.

In a closer look, P3 formed hydrogen bonds with His1377, Phe1461, Leu1462, Ser1464, Ser1468, Arg1548, Arg2412, and Asp2426 residues of ERα protein with a binding energy of– 7.1 kcal/mol and inhibition constant of 9.9 μM (Fig 3a, S2 Table in S1 File). Although none of the P3-interacting residues contained residues in the active site of ERα, it is suspected that the P3 may have acted as an allosteric ligand. In contrast, this peptide exactly interacted with the residues in the binding site of MCL-1 protein, including Asn260, Arg263, and Thr266, with a binding energy of– 7.2 kcal/mol and inhibition constant of 8.5 μM (Fig 3b, S2 Table in S1 File). It shows that P3 acts as an agonist or antagonist ligand against MCL-1. Therefore, P3 can appear different mechanisms to suppress breast cancer.

Fig 3. Molecular interactions of the best peptide-receptor complexes based on the binding energy from the molecular docking analysis.

Fig 3

a) P3-ERα complex, b) P3-MCL-1 complex, c) P5-PBP1a complex, d) P3-IARS complex, e) P4-DNA gyrase complex, and f) P5-DHFR complex. All hydrogen bonds have shown in dashed lines with yellow color.

In the case of the antibacterial activity of desired peptides, P3, P4, and P5 showed the ability to interact with various targets involved in the growth and development of bacteria. PBP1a is a membrane-associate protein that synthesizes the peptidoglycans needed to build the bacterial cell wall [46]. Hence, finding a ligand to inhibit this protein can open the way for designing new antibacterial agents. According to the results, P5 was able to interact with the binding site residues of PBP1a, including Lys669, Thr670, Thr672, and Tyr707, with a binding energy of– 7.5 kcal/mol and inhibition constant of 5.2 μM (Fig 3c, S2 Table in S1 File). On the other hand, IARS, an aminoacyl-tRNA synthetase, catalyzes the aminoacylation of tRNA by its cognate isoleucine which is essential for protein synthesis in bacteria, archaea, and eukaryotes [30]. Therefore, finding a ligand to inhibit it can be helpful for the inhibition of pathogens. Given this, P3 was able to interact with Gly45, Thr48, Asn50, Glu94, Gly551, and Gln554 residues of IARS with a binding energy of– 8.4 kcal/mol and inhibition constant of 1.2 μM (Fig 3d, S2 Table in S1 File). These interactions were covered the binding site of IARS through Gly551 and Gln554 residues so that P3 may act as inhibitor of IARS. In vitro previous literature has showed that mupirocin inhibits IARS of Staphylococcus aureus II-type mutant and S. aureus with a Ki value of 2.31 and 60 × 10−3 μM, respectively. In comparison, P3 also revealed a significant Ki value in silico that can be helpful to develop new antibacterial drugs. Furthermore, the inhibition of DNA synthesis is other way to suppress the growth and development of bacteria. One of the targets for this aim is DNA gyrase which introduce the negative supercoiling into bacterial DNA [47]. Our findings showed that P4 interacts with Asn54, Glu91, Lys93, Ser128, and Thr173 residues of DNA gyrase with a binding energy of– 7.0 kcal/mol and inhibition constant of 11.8 μM (Fig 3e, S2 Table S1 File). Although P4 did not interact with the residues of the DNA gyrase active site, it is hypothesized that it may inhibit the role of DNA gyrase by disrupting its function. In comparison, an in vitro previous work showed that TTGGQYAVAVARVVGD and LMMWVDSKNTVPKEWV peptide sequences were able to inhibit the E. coli DNA gyrase with a Ki value of 2.2 and 26.0 μM, respectively [48]. Also, DHFR, an metabolic enzyme for catalyzing dihydrofolic acid to tetrahydrofolic acid, has received a great deal of attention as a molecular target for bacterial resistance for decades [49]. Accordingly, Lee and coworkers showed that Trimethoprim, a selective inhibitor for bacterial DHFR, was able to bind to Streptococcus pneumoniae DHFR with an in vitro Ki value of 147 nM [50], whereas we showed that P5 can bind to S. aureus DHFR with an in silico Ki value of 0.74 μM and a binding energy of– 8.7 kcal/mol (Fig 3f, S2 Table in S1 File). Similar to DNA gyrase, P5 also interacted with residues outside DHFR active site, including Asn19, Thr47, Thr97, and Asp121, which may inhibit its function by disrupting its activity. However, our findings indicate that desired peptides are excellent candidates for developing new natural food preservative or drugs in the treatment of bacterial or cancerous diseases and will open new avenues for designing more selective and effective drugs. Furthermore, these peptides could recombinantly be produced in the plant expression systems to use as a fresh functional food [51, 52].

Conclusion

The introduction of one or more clinically active candidate molecules against a disease-related target is an important goal of drug discovery. In addition, these molecules have to provide adequate safety and drug-like properties. Therefore, peptides derived from dietary proteins such as milk proteins, in addition to being naturally occurring, have no side effects. Hence, our results revealed the discovery of peptides that have anti-breast cancer and antibacterial properties. Accordingly, peptides derived from whey protein with the use of both the pepsin and trypsin enzymes showed very good activity against MCF-7 breast cancer with cell viability of 7.13%. This suggests that the use of both enzymes is capable of producing peptides that exhibit high anticancer activity, whereas this treatment on casein protein produced peptides that had fewer anticancer effects than either treatment, which was used separately. In contrast, each enzyme treatment separately on whey protein showed the highest antibacterial activity against S. aureus and E. coli compared to the others. Followed by this, in the bioinformatics analysis section, we identified two highly efficient peptides that bind to specific targets in breast cancer and bacteria, one derived from casein protein (P3) and the other from whey protein (P5). This suggests that casein-derived peptides may not have been able to provide promising results in vitro due to their concentration distribution in the hydrolyzed mixture in compared to whey-derived peptides, although casein-derived peptides in turn have presented favorable anticancer and antibacterial activity. Therefore, our results introduce two very desirable natural food preservative or preclinical drug candidates that can be delivered to clinical and animal trials.

Supporting information

S1 File

(DOCX)

Acknowledgments

We would like to thank Prof. Ali Niazi and Dr. Mohammad Sadegh Taghizadeh for technical supporting at Institute of Biotechnology, Shiraz University, Shiraz, Iran.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infectious agents and cancer. 2021;16(1):1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.WHO. Breast cancer. 2021 March 26 [cited 2023 April 29]. https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
  • 3.Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022;7(1):1–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Meisel H. Biochemical properties of peptides encrypted in bovine milk proteins. Current medicinal chemistry. 2005;12(16):1905–19. doi: 10.2174/0929867054546618 [DOI] [PubMed] [Google Scholar]
  • 5.Meisel H, FitzGerald RJ. Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. Current pharmaceutical design. 2003;9(16):1289–96. doi: 10.2174/1381612033454847 [DOI] [PubMed] [Google Scholar]
  • 6.Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral research. 2003;58(3):209–15. doi: 10.1016/s0166-3542(02)00214-0 [DOI] [PubMed] [Google Scholar]
  • 7.Teschemacher H. Opioid receptor ligands derived from food proteins. Current pharmaceutical design. 2003;9(16):1331–44. doi: 10.2174/1381612033454856 [DOI] [PubMed] [Google Scholar]
  • 8.Schlimme E, Meisel H. Bioactive peptides derived from milk proteins. Structural, physiological and analytical aspects. Food/Nahrung. 1995;39(1):1–20. doi: 10.1002/food.19950390102 [DOI] [PubMed] [Google Scholar]
  • 9.Meisel H, Schlimme E. Inhibitors of angiotensin-converting-enzyme derived from bovine casein (casokinins). β-Casomorphins and Related Peptides: Recent Developments, Weinheim VCH. 1994:27–33.
  • 10.García JM, Udenigwe CC, Duitama J, Barrios AFG. Peptidomic analysis of whey protein hydrolysates and prediction of their antioxidant peptides. Food Science and Human Wellness. 2022;11(2):349–55. [Google Scholar]
  • 11.Mann B, Kumari A, Kumar R, Sharma R, Prajapati K, Mahboob S, et al. Antioxidant activity of whey protein hydrolysates in milk beverage system. Journal of food science and technology. 2015;52(6):3235–41. doi: 10.1007/s13197-014-1361-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Li G, Liu W, Wang Y, Jia F, Wang Y, Ma Y, et al. Functions and applications of bioactive peptides from corn gluten meal. Advances in food and nutrition research. 2019;87:1–41. doi: 10.1016/bs.afnr.2018.07.001 [DOI] [PubMed] [Google Scholar]
  • 13.Beltrán-Barrientos L, Hernández-Mendoza A, Torres-Llanez M, González-Córdova A, Vallejo-Córdoba B. Invited review: Fermented milk as antihypertensive functional food. Journal of dairy science. 2016;99(6):4099–110. doi: 10.3168/jds.2015-10054 [DOI] [PubMed] [Google Scholar]
  • 14.Bielecka M, Cichosz G, Czeczot H. Antioxidant, antimicrobial and anticarcinogenic activities of bovine milk proteins and their hydrolysates-a review. International Dairy Journal. 2021:105208. [Google Scholar]
  • 15.Baba WN, Maqsood S, editors. Novel antihypertensive and anticholesterolemic peptides from peptic hydrolysates of camel whey proteins. JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY; 2022: WILEY 111 RIVER ST, HOBOKEN 07030–5774, NJ USA. [Google Scholar]
  • 16.Khan FB, Ansari MA, Uddin S, Palakott AR, Anwar I, Almatroudi A, et al. Prospective Role of Bioactive Molecules and Exosomes in the Therapeutic Potential of Camel Milk against Human Diseases: An Updated Perspective. Life. 2022;12(7):990. doi: 10.3390/life12070990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhu L, Xiong H, Huang X, Guyonnet V, Ma M, Chen X, et al. Identification and molecular mechanisms of novel antioxidant peptides from two sources of eggshell membrane hydrolysates showing cytoprotection against oxidative stress: A combined in silico and in vitro study. Food Research International. 2022:111266. doi: 10.1016/j.foodres.2022.111266 [DOI] [PubMed] [Google Scholar]
  • 18.Mudgil P, Kamal H, Kilari BP, Salim MASM, Gan C-Y, Maqsood S. Simulated gastrointestinal digestion of camel and bovine casein hydrolysates: Identification and characterization of novel anti-diabetic bioactive peptides. Food chemistry. 2021;353:129374. doi: 10.1016/j.foodchem.2021.129374 [DOI] [PubMed] [Google Scholar]
  • 19.Kamal H, Jafar S, Mudgil P, Hamdi M, Ayoub MA, Maqsood S. Camel whey protein with enhanced antioxidative and antimicrobial properties upon simulated gastro-intestinal digestion. Nutrition and Health. 2022:02601060221122213. doi: 10.1177/02601060221122213 [DOI] [PubMed] [Google Scholar]
  • 20.Mohamed H, Ayyash M, Kamal-Eldin A. Effect of heat treatments on camel milk proteins–A review. International Dairy Journal. 2022:105404. [Google Scholar]
  • 21.Kumar D, Chatli MK, Singh R, Mehta N, Kumar P. Enzymatic hydrolysis of camel milk casein and its antioxidant properties. Dairy Science & Technology. 2016;96(3):391–404. [Google Scholar]
  • 22.Nielsen P, Petersen D, Dambmann C. Improved method for determining food protein degree of hydrolysis. Journal of food science. 2001;66(5):642–6. [Google Scholar]
  • 23.Gonelimali FD, Lin J, Miao W, Xuan J, Charles F, Chen M, et al. Antimicrobial properties and mechanism of action of some plant extracts against food pathogens and spoilage microorganisms. Frontiers in microbiology. 2018;9:1639. doi: 10.3389/fmicb.2018.01639 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Taghizadeh MS, Niazi A, Moghadam A, Afsharifar AR. Novel bioactive peptides of Achillea eriophora show anticancer and antioxidant activities. Bioorganic Chemistry. 2021;110:104777. doi: 10.1016/j.bioorg.2021.104777 [DOI] [PubMed] [Google Scholar]
  • 25.Taghizadeh MS, Retzl B, Muratspahić E, Trenk C, Casanova E, Moghadam A, et al. Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor. Scientific Reports. 2022;12(1):1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Taghizadeh MS, Niazi A, Moghadam A, Afsharifar AR. The potential application of the protein hydrolysates of three medicinal plants: cytotoxicity and functional properties. Journal of food science. 2020;85(10):3160–7. doi: 10.1111/1750-3841.15379 [DOI] [PubMed] [Google Scholar]
  • 27.Eiler S, Gangloff M, Duclaud S, Moras D, Ruff M. Overexpression, purification, and crystal structure of native ERα LBD. Protein Expression and Purification. 2001;22(2):165–73. [DOI] [PubMed] [Google Scholar]
  • 28.Han S, Caspers N, Zaniewski RP, Lacey BM, Tomaras AP, Feng X, et al. Distinctive attributes of β-lactam target proteins in Acinetobacter baumannii relevant to development of new antibiotics. Journal of the American Chemical Society. 2011;133(50):20536–45. [DOI] [PubMed] [Google Scholar]
  • 29.Li X, Hilgers M, Cunningham M, Chen Z, Trzoss M, Zhang J, et al. Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2, 4-diaminoquinazolines. Bioorganic & medicinal chemistry letters. 2011;21(18):5171–6. doi: 10.1016/j.bmcl.2011.07.059 [DOI] [PubMed] [Google Scholar]
  • 30.Nakama T, Nureki O, Yokoyama S. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. Journal of Biological Chemistry. 2001;276(50):47387–93. doi: 10.1074/jbc.M109089200 [DOI] [PubMed] [Google Scholar]
  • 31.Pelz NF, Bian Z, Zhao B, Shaw S, Tarr JC, Belmar J, et al. Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods. Journal of medicinal chemistry. 2016;59(5):2054–66. doi: 10.1021/acs.jmedchem.5b01660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sherer BA, Hull K, Green O, Basarab G, Hauck S, Hill P, et al. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorganic & medicinal chemistry letters. 2011;21(24):7416–20. doi: 10.1016/j.bmcl.2011.10.010 [DOI] [PubMed] [Google Scholar]
  • 33.Taghizadeh MS, Niazi A, Moghadam A, Afsharifar A. Experimental, molecular docking and molecular dynamic studies of natural products targeting overexpressed receptors in breast cancer. PloS one. 2022;17(5):e0267961. doi: 10.1371/journal.pone.0267961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lestari P, editor Antibacterial activity of hydrolysate protein from Etawa goat milk hydrolysed by crude extract bromelain. IOP Conference Series: Materials Science and Engineering; 2019: IOP Publishing.
  • 35.Jrad Z, El-Hatmi H, Adt I, Gouin S, Jardin J, Oussaief O, et al. Antilisterial activity of dromedary lactoferrin peptic hydrolysates. Journal of dairy science. 2019;102(6):4844–56. doi: 10.3168/jds.2018-15548 [DOI] [PubMed] [Google Scholar]
  • 36.Muhialdin BJ, Algboory HL. Identification of low molecular weight antimicrobial peptides from Iraqi camel milk fermented with Lactobacillus plantarum. PharmaNutrition. 2018;6(2):69–73. [Google Scholar]
  • 37.Wang R, Han Z, Ji R, Xiao Y, Si R, Guo F, et al. Antibacterial activity of trypsin-hydrolyzed camel and cow whey and their fractions. Animals. 2020;10(2):337. doi: 10.3390/ani10020337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Boohaker RJ, Lee MW, Vishnubhotla P, Perez JLM, Khaled AR. The use of therapeutic peptides to target and to kill cancer cells. Current medicinal chemistry. 2012;19(22):3794–804. doi: 10.2174/092986712801661004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Homayouni-Tabrizi M, Asoodeh A, Soltani M. Cytotoxic and antioxidant capacity of camel milk peptides: Effects of isolated peptide on superoxide dismutase and catalase gene expression. journal of food and drug analysis. 2017;25(3):567–75. doi: 10.1016/j.jfda.2016.10.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Murali C, Mudgil P, Gan C-Y, Tarazi H, El-Awady R, Abdalla Y, et al. Camel whey protein hydrolysates induced G2/M cellcycle arrest in human colorectal carcinoma. Scientific reports. 2021;11(1):1–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.De Simone C, Picariello G, Mamone G, Stiuso P, Dicitore A, Vanacore D, et al. Characterisation and cytomodulatory properties of peptides from Mozzarella di Bufala Campana cheese whey. Journal of peptide science: an official publication of the European Peptide Society. 2009;15(3):251–8. doi: 10.1002/psc.1093 [DOI] [PubMed] [Google Scholar]
  • 42.Pirtskhalava M, Vishnepolsky B, Grigolava M, Managadze G. Physicochemical Features and Peculiarities of Interaction of AMP with the Membrane. Pharmaceuticals. 2021;14(5):471. doi: 10.3390/ph14050471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gong Z, Ikonomova SP, Karlsson AJ. Secondary structure of cell‐penetrating peptides during interaction with fungal cells. Protein Science. 2018;27(3):702–13. doi: 10.1002/pro.3364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Xiang N, Lyu Y, Zhu X, Bhunia AK, Narsimhan G. Effect of physicochemical properties of peptides from soy protein on their antimicrobial activity. Peptides. 2017;94:10–8. doi: 10.1016/j.peptides.2017.05.010 [DOI] [PubMed] [Google Scholar]
  • 45.Silakari O, Singh P. Chapter 6—Molecular docking analysis: Basic technique to predict drug-receptor interactions. Concepts and Experimental Protocols of Modelling and Informatics in Drug Design. 2021:131–55. [Google Scholar]
  • 46.Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS microbiology reviews. 2008;32(2):234–58. doi: 10.1111/j.1574-6976.2008.00105.x [DOI] [PubMed] [Google Scholar]
  • 47.Marchese A, Debbia EA. The role of gyrA, gyrB, and dnaA functions in bacterial conjugation. Annals of microbiology. 2016;66(1):223–8. [Google Scholar]
  • 48.Nakanishi A, Imajoh-Ohmi S, Hanaoka F. Characterization of the interaction between DNA gyrase inhibitor and DNA gyrase of Escherichia coli. Journal of Biological Chemistry. 2002;277(11):8949–54. doi: 10.1074/jbc.M111278200 [DOI] [PubMed] [Google Scholar]
  • 49.Wróbel A, Arciszewska K, Maliszewski D, Drozdowska D. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors. The Journal of antibiotics. 2020;73(1):5–27. doi: 10.1038/s41429-019-0240-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lee J, Yennawar NH, Gam J, Benkovic SJ. Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae. Biochemistry. 2010;49(1):195–206. doi: 10.1021/bi901614m [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Hashemi S, Niazi A, Baghizadeh A, Taghizadeh MS. Successful use of Nicotiana tabacum hairy roots for the recombinant production of Cecropin A peptide. Biotechnology and Applied Biochemistry. 2022;69(3):876–86. doi: 10.1002/bab.2158 [DOI] [PubMed] [Google Scholar]
  • 52.Sadeghi Ghahderijani N, Niazi A, Ebrahimie E, Moghadam A, Taghizadeh MS. Assessment of the efficiency of hairy roots induction using soybean, sugar beet and tobacco explants. Journal of Plant Molecular Breeding. 2018;6(1):61–72. [Google Scholar]

Decision Letter 0

Ghulam Mustafa

19 Apr 2023

PONE-D-23-05337In vitro and in silico studies for identification bioactive peptides from camel milk protein hydrolysatesPLOS ONE

Dear Dr. Ezzatpanah,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 03 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ghulam Mustafa, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

""Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Minor modifications required:

1. Indicate the bioactivities that are being investigated in the study in your title - i.e. you can add anti-cancer and anti-bacterial bioactivities in the title.

2. Line 43: Remove the link and reference it according to the guidelines.

3. Line 80: State the storage conditions between the period of purchase and analysis.

4. Line 90: Avoid using ddH2O, instead use distilled water/double distilled water accordingly.

5. Table 4 in the reference "" ext-link-type="uri" xlink:type="simple">https://doi.org/10.1016/j.foodchem.2021.131444" has a list of camel milk-derived bioactive peptides with potential antibacterial properties. Check it out and use it in your discussion to see if there are any similar trends.

Reviewer #2: The manuscript “In vitro and in silico studies for identification bioactive peptides from camel milk protein hydrolysates” is a manuscript that investigates isolating the protein from camel milk and hydrolyzing it using two different enzymes to achieve the hydrolysate fractions with biological activities. In my opinion, the study has been well-designed, and the manuscript covers the objectives. However, some points should be carefully addressed by the authors. I believe this manuscript needs MAJOR Modification to be suitable for publishing in the journal.

Comments:

1. Title: Add “the” and “of” to the title. In vitro and in silico studies for the identification of bioactive peptides from camel milk protein hydrolysates

2. Introduction- Page 9, Line 43: use the references according to the journal requirement for web pages.

3. Materials and Methods- Page 11, Line 93: Why did the authors select 12 h for hydrolysis of the proteins?

4. Did the authors measure the DH of the parent protein as a control? If not, how do they justify that the DH of protein hydrolysates is higher or lower than the parent protein?

5. The above question is important about the bioactivities of the protein hydrolysates. How do they claim that the anticancer activity of protein hydrolysates is higher than the parent proteins? Please justify.

6. Why do authors use only 4 bacteria for the antibacterial activities? For antibacterial studies, usually, a combination of gram-negative and gram-positive bacteria should be used. Justify please.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jul 12;18(7):e0288260. doi: 10.1371/journal.pone.0288260.r002

Author response to Decision Letter 0


27 May 2023

Reviewer #1: Minor modifications required:

1. Indicate the bioactivities that are being investigated in the study in your title - i.e. you can add anti-cancer and anti-bacterial bioactivities in the title.

Response: Dear Reviewer, we would like to thank you for your time and for helping improve our manuscript with your valuable comments.

Title was revised as you wished.

2. Line 43: Remove the link and reference it according to the guidelines.

Response: we revised it according to the journal guideline.

3. Line 80: State the storage conditions between the period of purchase and analysis.

Response: we added it in the main text (line 81).

4. Line 90: Avoid using ddH2O, instead use distilled water/double distilled water accordingly.

Response: we revised it as you wished.

5. Table 4 in the reference "https://doi.org/10.1016/j.foodchem.2021.131444" has a list of camel milk-derived bioactive peptides with potential antibacterial properties. Check it out and use it in your discussion to see if there are any similar trends.

Response: Thank you for your good suggestion. We included it in the discussion (lines 221-228).

Reviewer #2: The manuscript "In vitro and in silico studies for identification bioactive peptides from camel milk protein hydrolysates" is a manuscript that investigates isolating the protein from camel milk and hydrolyzing it using two different enzymes to achieve the hydrolysate fractions with biological activities. In my opinion, the study has been well-designed, and the manuscript covers the objectives. However, some points should be carefully addressed by the authors. I believe this manuscript needs MAJOR Modification to be suitable for publishing in the journal.

Comments:

1. Title: Add "the" and "of" to the title. In vitro and in silico studies for the identification of bioactive peptides from camel milk protein hydrolysates

Response: Dear Reviewer, we would like to thank you for your time and for helping improve our manuscript with your valuable comments.

Title was edited as you wished.

2. Introduction- Page 9, Line 43: use the references according to the journal requirement for web pages.

Response: we revised it according to the journal guideline.

3. Materials and Methods- Page 11, Line 93: Why did the authors select 12 h for hydrolysis of the proteins?

Response: This time was chosen due to (i) Ensure the complete hydrolysis of the protein by the enzyme, that is, the enzyme has the opportunity to recognize and cut all its recognition sites (ii) Since our aim was to evaluate the antibacterial and anticancer activities, therefore we wanted to ensure the production of 1-7 kD peptides because the peptides with these sizes usually exhibit these activities (https://doi.org/10.1098/rsob.200004; https://doi.org/10.1128/AAC.02369-13). Also, in a study by Wang et al. (https://doi.org/10.3390/ani10020337), they stated that hydrolysis of camel milk proteins for 12h could produce peptides for killing their desired bacteria (lines 228-232).

4. Did the authors measure the DH of the parent protein as a control? If not, how do they justify that the DH of protein hydrolysates is higher or lower than the parent protein?

Response: Thank you for your precious question. At time 0, no hydrolysis has taken place, so this in turn represents the degree of hydrolysis of the original proteins initially. However, we added the following sentence: “At time 0, no hydrolysis has taken place, so that the degree of hydrolysis of the parent proteins varied from 1.9 to 2.8% and increased over time with the addition of enzymes (Fig. 1)" in lines 195-197 to avoid any misunderstanding.

5. The above question is important about the bioactivities of the protein hydrolysates. How do they claim that the anticancer activity of protein hydrolysates is higher than the parent proteins? Please justify.

Response: According to the Fig. 2, we measured anticancer activity of parent proteins and hydrolysates, therefore whey and casein proteins (parent proteins that used as control) respectively killed approximately 30% and 10% of total cancerous cells, which is lower than anticancer activity of hydrolysates (Fig. 2). Also, it is better to say that since we boiled the mixture after hydrolysis to inactivate the enzyme, all of proteins, including enzyme and parent proteins were removed using centrifugation. Therefore, there are only peptides in the mixture. But if there are parent proteins in the mixture, they are inactive. However, we clarified it by adding a sentence in lines 250-252.

6. Why do authors use only 4 bacteria for the antibacterial activities? For antibacterial studies, usually, a combination of gram-negative and gram-positive bacteria should be used. Justify please.

Response: Thank you so much for your good question. As you said we also used a combination of gram-negative and gram-positive bacteria (3 gram-negatives bacteria, including Klebsiella pneumoniae (PTCC 1053), Pseudomonas aeruginosa (PTCC 1074), and Escherichia coli (PTCC 1330); and 1 gram-positive bacteria, including Staphylococcus aureus (PTCC 1112)). They are from different families and commonly use in antibacterial studies, because they cause deadly diseases in humans. Therefore, we decided to choose them for evaluating antibacterial tests.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Ghulam Mustafa

22 Jun 2023

In vitro and in silico studies for the identification of anti-cancer and antibacterial peptides from camel milk protein hydrolysates

PONE-D-23-05337R1

Dear Dr. Ezzatpanah,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ghulam Mustafa, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments have been addressed. The manuscript can be accepted in its current form. Thanks for the revision.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Ghulam Mustafa

3 Jul 2023

PONE-D-23-05337R1

In vitro and in silico studies for the identification of anti-cancer and antibacterial peptides from camel milk protein hydrolysates

Dear Dr. Ezzatpanah:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ghulam Mustafa

Academic Editor

PLOS ONE


Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES